Cited by 208Genetic factors in colorectal cancerAdrenal and Paraganglionic TumorsChromatin Remodeling and Cancer

Adrenocortical carcinoma is a Lynch syndrome-associated cancer

Open access
Raymond, Victoria M., Everett, Jessica N., Furtado, Larissa V., Gustafson, Shanna L., Jungbluth, Chelsy R., Gruber, Stephen B., Hammer, Gary D., Stoffel, Elena M. +3 more·2013·Journal of Clinical Oncology

Abstract

PURPOSE: Adrenocortical carcinoma (ACC) is an endocrine malignancy with a poor prognosis. The association of adult-onset ACC with inherited cancer predisposition syndromes is poorly understood. Our study sought to define the prevalence of Lynch syndrome (LS) among patients with ACC. PATIENTS AND METHODS: One hundred fourteen patients with ACC were evaluated in a specialized endocrine oncology clinic and were prospectively offered genetic counseling and clinical genetics risk assessment (group 1). In addition, families with known mismatch repair (MMR) gene mutations that were recorded in the University of Michigan Cancer Genetics Registry were retrospectively reviewed for the presence of ACC (group 2). ACC tumors from patients with LS were tested for microsatellite instability and immunohistochemistry (IHC) to evaluate for MMR deficiency. RESULTS: Ninety-four (82.5%) of 114 patients with ACC underwent genetic counseling (group 1). Three individuals (3.2%) had family histories suggestive of LS. All three families were found to have MMR gene mutations. Retrospective review of an additional 135 MMR gene-positive probands identified two with ACC (group 2). Four ACC tumors were available (group 1, 3; group 2, 1). All four tumors were microsatellite stable; three had IHC staining patterns consistent with germline mutation status. CONCLUSION: The prevalence of LS among patients with ACC is 3.2%, which is comparable to the prevalence of LS in colorectal and endometrial cancer. Patients with ACC and a personal or family history of LS tumors should be strongly considered for genetic risk assessment. IHC screening of all ACC tumors may be an effective strategy for identifying patients with LS.

Integrity signals

Registry

Crossref · 10.1200/jco.2012.48.0988

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • All tested ACCs were microsatellite stable at the usual microsatellite markers.

    “Immunohistochenistry was informative in most cases; however, all tested ACCs were microsatellite stable at the usual microsatellite markers.”

    From Adrenocortical carcinoma (2014) · cites this paper as [62]

  • The prevalence of Lynch syndrome in patients with ACC is ∼3%, comparable to the prevalence in colorectal and endometrial cancer (2% to 5%).

    “Recently, a systematic analysis has defined the prevalence of Lynch syndrome in patients with ACC to be ∼3%, comparable to the prevalence in colorectal and endometrial cancer, estimated at 2% to 5% (62).”

    From Adrenocortical carcinoma (2014) · cites this paper as [62]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Raymond, V. M., Everett, J. N., Furtado, L. V., Gustafson, S. L., Jungbluth, C. R., Gruber, S. B., Hammer, G. D., Stoffel, E. M., Greenson, J. K., Giordano, T. J., & Else, T.
Affiliations
University of Michigan (US)
Venue
Journal of Clinical Oncology
Published
2013-08-20
Volume
31
Issue
24
Pages
3012-3018
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2100692201
Cited by
208
References
43
Citations by year
2026: 13 · 2025: 15 · 2024: 13 · 2023: 10 · 2022: 19 · 2021: 27 · 2020: 18 · 2019: 15 · 2018: 21 · 2017: 16 · 2016: 16 · 2015: 12 · 2014: 7 · 2013: 5
FWCI
9.81
Type
journal article
Language
en
Open access
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (CA014089, CA046592)
  • National Cancer Institute (CA 046592, K07CA120448, P30CA046592, P30CA014089)
  • National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007245, P30DK020572)
Topics
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
  • Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
adrenocortical carcinoma, Lynch syndrome, mismatch repair deficiency, microsatellite instability, hereditary cancer predisposition, immunohistochemistry screening, genetic counseling, endocrine malignancy
MeSH terms
Adrenal Cortex Neoplasms, Adult, Colorectal Neoplasms, Hereditary Nonpolyposis, Female, Humans, Immunohistochemistry, Male, Middle Aged, Prospective Studies, Adrenocortical Carcinoma, Genetic Predisposition to Disease, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review